RxDoctor Payments Data

Edward Ellison, MD

Urology · Coeur D' Alene, IDNPI 1346375235

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.5% of the total across 331 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.

$7,399in general payments, 2019–2025

Across 331 payments — averaging $22.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$721
  • Dendreon Pharmaceuticals LLC$562
  • Sumitomo Pharma America, Inc.$466
  • AbbVie$398
  • Boston Scientific$355
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$7,06395%
  • Education$3365%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,399 in reported general payments places this provider in the 85th percentile of 55 urology providers in Idaho.

See all urology providers in Idaho

Medicare billing

Part B allowed, 2024
$511,903
Medicare patients
673
Services billed
14,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide250$3,411,444
OrgovyxRelugolix526$1,355,813
ErleadaApalutamide46$641,221
YonsaAbiraterone Acet,submicronized17$194,594
Abiraterone Acetate88$159,735
GemtesaVibegron109$60,309
MyrbetriqMirabegron81$58,707
Tamsulosin Hcl386$6,400
Tolterodine Tartrate ErTolterodine Tartrate18$2,897
Testosterone Cypionate12$1,447
Finasteride81$1,320
Silodosin17$1,279
Bicalutamide12$1,090
Oxybutynin Chloride34$772
Alfuzosin Hcl ErAlfuzosin Hcl14$415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,398$3,470,150331 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$466$1,416,122635 claims
Johnson & JohnsonErleada$721$641,22146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 urology providers in Idaho.

Other urology in Coeur D' Alene

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →